Citius Pharmaceuticals’ Lymphir and Keytruda Combo Shows Promising Clinical Outcomes, Earning a Buy Rating
Michael Okunewitch, an analyst from Maxim Group, maintained the Buy rating on Citius Pharmaceuticals (CTXR – Research Report). The ...
Healthline8d
All About Keytruda
Keytruda (pembrolizumab) is a prescription drug that’s used to treat certain forms of cancer. Keytruda comes as an intravenous (IV) infusion (an injection into your vein given over time ...
Nasdaq1mon
Is Merck Stock a Buy?
Anyone crafting a bull case for the pharmaceutical giant Merck (NYSE: MRK) should include Keytruda as the company's best asset. The cancer drug has been Merck's top-selling medicine and its ...
Nasdaq20d
Merck’s KEYTRUDA® (pembrolizumab) Receives 30th Approval From European Commission With Two New Indications in Gynecologic Cancers
KEYTRUDA plus chemotherapy is the first approval in the EU for an anti-PD-1 therapy combined with chemotherapy only for patients with primary advanced or recurrent endometrial carcinoma regardless ...
Business Insider6d
IO Biotech reports data on IO102-IO103 vaccine in combination with KEYTRUDA
IO Biotech (IOBT) announced data from the NSCLC cohort in the company’s Phase 2 basket trial of IO102-IO103, the company’s lead investigational candidate, given in combination with Merck’s anti-PD-1 ...
Merck earnings top estimates amid solid demand for Keytruda cancer drug
Merck and Co. (NYSE:MRK) has posted better-than-anticipated third-quarter profit thanks to solid demand for its crucial cancer treatment Keytruda, although the drugmaker warned of ongoing sluggishness ...
Merck posts late-stage trial win for Keytruda in head and neck cancer
Merck (NYSE:MRK) announced Tuesday that its Phase 3 KEYNOTE-689, designed to evaluate its anti-PD-1 therapy Keytruda as a ...
Cure Today29d
Keytruda Regimen May Improve Event-Free Survival in Head and Neck Squamous Cell Carcinoma
KEYNOTE-689 trial showed significant improvement in event-free survival for stage 3 or 4A resected head and neck squamous cell carcinoma with Keytruda. Keytruda regimen included neoadjuvant therapy, ...
Cure Today6d
Keytruda Has Long-Term Survivorship Implications in Early Triple-Negative Breast Cancer
Among patients with early triple-negative breast cancer, treatment with Keytruda (pembrolizumab) demonstrated real-world evidence of immune-related adverse effects (irAEs) comparable with KEYNOTE-522, ...
pharmaphorum9d
ESMO21: Libtayo extends survival in first-line NSCLC, challenging Keytruda
That's less impressive than the 50% reduction in death in Merck's KEYNOTE-189 trial of Keytruda in non-squamous NSCLC – which was behind its approval for first-line NSCLC alongside chemo in 2018 ...
MarketWatch1mon
Merck: Favezelimab/Keytruda Combo Study Misses Goal in Colorectal Cancer
Merck & Co. on Wednesday said a late-stage study of a combination including its blockbuster cancer drug Keytruda missed its goal in certain patients with colorectal cancer. The Rahway, N.J ...